CDK inhibitor (original) (raw)
A CDK (cyclin-dependent kinase) inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a CDK4/6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. Several compounds are in clinical trials.
| Property | Value |
|---|---|
| dbo:abstract | A CDK (cyclin-dependent kinase) inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a CDK4/6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. Several compounds are in clinical trials. (en) CDK-Inhibitoren sind eine relativ neue Gruppe von Arzneistoffen, die zur Behandlung von verschiedenen Krebserkrankungen (z. B. Brustkrebs) eingesetzt werden. CDK-Inhibitoren sind Hemmstoffe der Proteinkinasen Cyclin-abhängige Kinasen (engl. cyclin-dependent kinases, CDKs), die bei der Steuerung des Zellzyklus und somit bei der Zellproliferation eine Rolle spielen. Proteinkinasen sind Enzyme, die andere Proteine an bestimmten Stellen phosphorylieren. Beim Menschen existieren 20 verschiedene CDKs. (de) |
| dbo:thumbnail | wiki-commons:Special:FilePath/CDK2-Selective_inhibitor.png?width=300 |
| dbo:wikiPageID | 25397709 (xsd:integer) |
| dbo:wikiPageLength | 13455 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1106310763 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Cancer dbr:Priority_review dbr:Breast_cancer dbr:Ribociclib dbr:Cyclin-dependent_kinase dbr:US_FDA dbr:Zotiraciclib dbr:Melanoma dbr:G1_Therapeutics dbr:Letrozole dbr:Leukemia dbr:Small-cell_carcinoma dbr:Hormone_receptor dbr:Cell_(biology) dbr:Trilaciclib dbr:HER2 dbr:Abemaciclib dbr:Estrogen_receptor dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbr:Palbociclib dbc:Protein_kinase_inhibitors dbr:Tissue_(biology) dbr:Bone_marrow_suppression dbr:HER2_negative dbr:Accelerated_Approval dbr:Solid_tumors dbr:CDK2 dbr:CDK4 dbr:CDK6 dbr:File:CDK2-Selective_inhibitor.png dbr:P1446A-05 |
| dbp:wikiPageUsesTemplate | dbt:Sectionlink dbt:About dbt:Anchor dbt:As_of dbt:Reflist dbt:Short_description dbt:Extracellular_chemotherapeutic_agents |
| dcterms:subject | dbc:Protein_kinase_inhibitors |
| rdf:type | yago:Inhibitor114724436 yago:Matter100020827 yago:PhysicalEntity100001930 yago:Substance100020090 yago:WikicatProteinKinaseInhibitors |
| rdfs:comment | A CDK (cyclin-dependent kinase) inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a CDK4/6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. Several compounds are in clinical trials. (en) CDK-Inhibitoren sind eine relativ neue Gruppe von Arzneistoffen, die zur Behandlung von verschiedenen Krebserkrankungen (z. B. Brustkrebs) eingesetzt werden. CDK-Inhibitoren sind Hemmstoffe der Proteinkinasen Cyclin-abhängige Kinasen (engl. cyclin-dependent kinases, CDKs), die bei der Steuerung des Zellzyklus und somit bei der Zellproliferation eine Rolle spielen. Proteinkinasen sind Enzyme, die andere Proteine an bestimmten Stellen phosphorylieren. Beim Menschen existieren 20 verschiedene CDKs. (de) |
| rdfs:label | CDK-Inhibitor (de) CDK inhibitor (en) |
| owl:sameAs | freebase:CDK inhibitor yago-res:CDK inhibitor wikidata:CDK inhibitor dbpedia-de:CDK inhibitor dbpedia-sl:CDK inhibitor https://global.dbpedia.org/id/fzPg |
| prov:wasDerivedFrom | wikipedia-en:CDK_inhibitor?oldid=1106310763&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/CDK2-Selective_inhibitor.png |
| foaf:isPrimaryTopicOf | wikipedia-en:CDK_inhibitor |
| is dbo:class of | dbr:Trilaciclib |
| is dbo:wikiPageRedirects of | dbr:Purvalanol_A dbr:CDK4/6_inhibitor |
| is dbo:wikiPageWikiLink of | dbr:Michele_Pagano_(biochemist) dbr:Boehringer_Ingelheim dbr:Breast_cancer dbr:Cyclin-dependent_kinase dbr:Cyclin-dependent_kinase_4 dbr:Zotiraciclib dbr:Epithelioid_sarcoma dbr:G1_Therapeutics dbr:Small-cell_carcinoma dbr:Trilaciclib dbr:Abemaciclib dbr:Kinase dbr:Gregory_Hannon dbr:Targeted_therapy dbr:Bone_marrow_suppression dbr:Neutropenia dbr:Selective_estrogen_receptor_degrader dbr:Restriction_point dbr:Purvalanol_A dbr:CDK4/6_inhibitor |
| is dbp:class of | dbr:Trilaciclib |
| is foaf:primaryTopic of | wikipedia-en:CDK_inhibitor |
